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To dissect the function of matrix metalloproteinases
(MMPs) involved in cellular migration in vivo, we
undertook both a forward chemical genomic screen
and a functional approach to discover modulators
of melanophore (pigment cell) migration in Xenopus
laevis. We identified the 8-quinolinol derivative NSC
84093 as affecting melanophore migration in the
developing embryo and have shown it to act as
a MMP inhibitor. Potential targets of NSC 84093
investigated include MMP-14 and MMP-2. MMP-14
is expressed in migrating neural crest cells from
which melanophores are derived. MMP-2 is ex-
pressed at the relevant time of development and in
a pattern that suggests it contributes tomelanophore
migration. Morpholino-mediated knockdown of both
MMPs demonstrates they play a key role in melano-
phoremigration and partially phenocopy the effect of
NSC 84093.
INTRODUCTION
Over the last 10 years, chemical genomics has received a lot of
interest from the chemical biology community (Schreiber, 1998;
Spring, 2005). With the aid of appropriate high-throughput
synthesis and well-defined biological screening strategies, it is
feasible to identify specific small molecule inhibitors ofmany bio-
logical events (Adams and Levin, 2006; Ding and Schultz, 2004;
Stockwell, 2000). The approach provides fundamental chal-
lenges for synthetic and analytical chemistry on the one hand,
and novel opportunities to manipulate biological systems on
the other (Ansari, 2007; Knight and Shokat, 2007; Schreiber,
1998; Yeh and Crews, 2003).
Small molecule intervention offers a complimentary approach
to loss-of-function mutations in the analysis of complex, multi-
component biological processes such as cell signaling and
morphogenesis. Whole animal high-throughput chemical
genomic screens have been developed for Drosophila, Caeno-
rhabditis elegans, zebrafish, and Xenopus (Carroll et al., 2003;Chemistry & Biology 16,Kwok et al., 2006; Tomlinson et al., 2005; Zon and Peterson,
2005). An advantage of chemical genomic screens over muta-
genesis screens is that they allow for temporal control of protein
function.
With respect to vertebrate development, the number of
compounds so far identified with specific developmental effects
is small. Such compounds often come from natural sources, as
in the case of cyclopamine, which blocks the hedgehog pathway
(Cooper et al., 1998). The recent use of zebrafish (Zon and Peter-
son, 2005) and Xenopus (Fukumoto et al., 2005; Tomlinson et al.,
2005) in chemical genomic screening has opened up new
opportunities. To date, chemical genomic screens have identi-
fied compounds that modulate embryonic development
(Anderson et al., 2007; Burns et al., 2005; Fukumoto et al.,
2005; Kwok et al., 2006; Mathew et al., 2007; Peterson et al.,
2000; Singh et al., 2005; Tomlinson et al., 2005; Yu et al., 2008)
and help with drug target discovery (Adams and Levin, 2006;
Langheinrich et al., 2002; Lunn and Stockwell, 2005), target vali-
dation, and toxicological studies (Langheinrich, 2003; Peterson
et al., 2001). Chemical genomics is also becoming increasingly
important in identifying new molecular tools for studying devel-
opmental processes. Recent advances include the use of
a compound (MoTP) to specifically ablate embryonic melano-
phores (Yang and Johnson, 2006). This allowed the important
discovery of melanophore stem cell populations in developing
zebrafish embryos (Yang et al., 2007; Yang and Johnson, 2006).
The study presented here focused on melanophores as an
in vivo model for cellular migration. The main function of melano-
phores (melanocytes in higher vertebrates) is pigment produc-
tion, which aids camouflage (and thus reduces predation) and
protects the skin from deleterious agents such as free radicals
and ultraviolet irradiation (UV) (Lamason et al., 2005; Riley,
1997). In the developing Xenopus embryo, as in all vertebrates,
the melanophores arise as melanoblasts from a pluripotent
neural crest cell (NCC) population on the dorsal side of the neural
tube (Le Douarin and Dupin, 2003). Melanoblasts are potentially
specified to become melanophores before migration as shown
by XlDCT expression (Kumasaka et al., 2003; see Figure S2 avail-
able online). They then actively migrate extensive distances to
form two distinctive pigment stripes in the embryo, the lateral
and dorsal stripes (Collazo et al., 1993; Kumasaka et al., 2003);
see Figures 1A and 1C). The lateral pigment stripe consists of93–104, January 30, 2009 ª2009 Elsevier Ltd All rights reserved 93
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MMPs in Xenopus Melanophore MigrationFigure 1. Pigmentation Pattern Seen with
Wild-Type and NSC 84093-Treated Embryos
(A) Schematic representation of the migratory
pathways taken by the lateral pigment (red arrow)
and dorsal pigment (blue arrow) stripe melano-
phores of a stage 38 wild-type embryo. A1 shows
the lateral side of the embryo, whereas A2 shows
a transverse view.
(B) Structure of NSC 84093 (7-[(S)-[(4-methylphe-
nyl)amino](phenyl)methyl]quinolin-8-ol) with the
quinoline moiety highlighted by the box.
(C) Normal pigmentation patterns seen in wild-
type embryos at stage 38 (1–3). C3 shows a close
up of the dorsal trunk section of C1.
(D) Disrupted pigmentation pattern seen with the
application of 1 mM NSC 84093, showing that the
treated embryos lack pigment cells in the ventral
part of the dorsal pigment stripe (1–3). D3 shows
a close up of the dorsal trunk section of D1
(same position as for C3).
(E and F) Sections showing internal melanophore
localization of stage 38 embryos. E1 is a sagittal
section with the anterior half of the embryo shown,
E2 is a longitudinal section cut at the level of the
neural tube, and E3 is a transverse section,
midway on the anterior-posterior axis. F 1, 2, and 3 are sections of NSC 84093-treated (1 mM) embryos in the same plane and orientation as for E 1, 2, and 3.
Diamond (A) represents the lateral pigment stripe, and arrowhead (:) represents the melanophores of the dorsal pigment stripe on the dorsal side of the tail
and those that have migrated to the ventral side of the tail. Black arrows show the position of individual melanophores, and white arrows show the position of
the pineal body. s represents somites; Nt, neural tube; No, notochord. All embryos are shown in lateral view, with anterior to the left, except C2 and D2, which
are dorsal views.a triangular-shaped patch of melanophores, on both sides of the
embryo trunk (Collazo et al., 1993). The dorsal stripe forms
a continuous band circumnavigating the embryo tail. Melano-
phoremigration is initiated between stage 24 and 30 in a progres-
sive anterior to posterior wave (Kumasaka et al., 2003). The
migration route in respect to the internal structures of the embryo
is between the somites and the neural tube, for both pigment
stripes (Collazo et al., 1993). Importantly melanophores have
also been trackedmigrating 2–6 somite lengths in a caudal direc-
tion (Collazo et al., 1993; Krotoski et al., 1988).
The study of melanophore migration has potential implica-
tions for human health. Melanomas, which originate from mela-
nocytes in the skin, are one of the most dangerous forms of
skin cancer because they are highly invasive and resistant to
treatment. Human melanomas are known to express a number
of matrix metalloproteinases (MMPs), including MMP-14 and
MMP-2 (Hofmann et al., 2000). The role of MMP-14 and
MMP-2 in melanoma progression is consistent with other
cancers, where their expression levels correlate with increased
progression and invasiveness, and hence metastasis (Hofmann
et al., 2000). The known model of MMP-14/TIMP-2 activation of
MMP-2 is also present in metastatic melanoma (Hofmann et al.,
2000). The ability to block melanophore migration can be
considered a starting point for therapeutic intervention in the
treatment of metastatic melanoma (Haass et al., 2005). It is
now increasingly recognized that cell motility and invasion
could provide a rich source of novel targets for cancer therapy,
and that appropriate inhibitors might prevent both metastasis
and neoangiogenesis (Eccles et al., 2005). Therefore, one of
the possible outputs of chemical genomic studies on melano-
phore migration might be the identification of novel anticancer
lead compounds.94 Chemistry & Biology 16, 93–104, January 30, 2009 ª2009 ElseviIn this study, we identify a small molecule compound (NSC
84093) that selectively inhibits the migration of Xenopusmelano-
phores. We characterized this compound further and found that
it has the ability to act as a putative MMP inhibitor. We further
show that morpholino (MO)-mediated knockdown of Xenopus
MMP-2 and MMP-14 can partially phenocopy the addition of
NSC 84093 and inhibit melanophore migration. We conclude
that MMPs are crucial for melanophore migration in vivo.
RESULTS
NSC 84093 Prevents Melanophore Migration
by the Dorsal Pathway
We have performed a developmental chemical genomic screen
of 3000 compounds (Tomlinson et al., 2009) to identify pheno-
types associated with pigment cell development. We have iden-
tified 40 compounds, producing varying phenotypes. Com-
pound NSC 84093 (Figure 1B) gave a dramatic pigmentation
phenotype (shown in Figure 1D) when applied to the embryos
at as little as 1 mM concentration (see Figure S1 for a dose-
response curve). The continuous dorsal pigment stripe seen in
wild-type embryos (Figures 1C and 1E) failed to form. Instead,
in NSC 84093-treated embryos, a segmented pattern of pigment
could be seen along the dorsal side of the embryo (Figures 1D
and 1F). The ventral side of the tail also lacked the majority of
melanophores (Figure 1, D1, indicated by the triangle symbol).
The lateral pigment stripe was present and the melanophores
from the pineal body in the head migrated normally (Figure 1,
D1, indicated by the diamond and the white arrows). The mela-
nophores moved from the dorsal side of the neural tube to be
situated on either side (Figure 1, D2). Closer inspection of the
segmented dorsal pigment stripe in the treated embryos showeder Ltd All rights reserved
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MMPs in Xenopus Melanophore MigrationFigure 2. Application and Release Experiments to Dissect the Developmental Window of NSC 84093’s Molecular Target
(A–D) Application of NSC 84093 (1 mM) at stage 15 and subsequent release at stage 26 (A), 28 (B), 30 (C), and 32 (D).
(E–H) Application of NSC 84093 (1 mM) at stage 26 (E), 28 (F), 30 (G), and 32 (H). Black arrow shows migrating melanophores. The additional box for each embryo
shows a close up of the dorsal stripe in the tail region. 5 represents the dorsal pigment stripe. All embryos are shown in lateral view, with anterior to the left.that the melanophores are constrained to clearly defined bound-
aries, giving a sharply segmented appearance (Figure 1, D3).
Sections clearly showed that the melanophores were able to
migrate between the somites and the neural tube, but failed to
migrate any further (Figures 1E and 1F).
NSC 84093 Exerts Its Effect at an Early Point
in Migration
To determine the developmental window in which NSC 84093
acts, we applied the compound at different stages of develop-
ment (Figures 2A–2H). Melanoblasts begin to migrate away
from the neural tube around stage 26 (Collazo et al., 1993). We
applied the compound before migration started at stage 15
and then removed it at various time points. Applying the
compound from stage 15 to 24 did not give a phenotype (data
not shown). Applying the compound from stage 15 to 26 showed
that NSC 84093 causes the segmented pattern in the anterior
dorsal trunk region (Figure 2A). However, the migration of
pigment cells to the ventral side of the tail was unperturbed
(Figure 2A). Applying the compound at stage 15 to stages 28,
30, and 32 (Figures 2B–2D) showed an increasing inhibition of
pigment cell migration to the ventral side of the tail. When the
compound was added at stage 26 to 38, the segmentation and
a loss of pigment cells in the ventral tail region was seen (Fig-
ure 2E). This effect on ventral tail melanophore migration is less-
ened when the compound is applied at later stages (and left to
stage 38) (Figures 2E–2H). The segmented pattern in the anterior
dorsal region of the trunk was still observed. These results sug-
gested that a developmental time window between stages 26
and 32 is critical for the molecular action of NSC 84093, with
respect to melanophore migration to the ventral side of the tail.
These results were confirmed when the compound was applied
at stage 26 and removed at stage 32. This caused the same
phenotype as that shown in Figure 2D (data not shown).
Using the specific molecular marker XlDCT (Kumasaka et al.,
2003), we investigated the segmented phenotype further by
visualizing the location of melanoblasts on the dorsal side of
the neural tube. In the wild-type embryo, at stage 26, the
XlDCT-expressing cells are randomly distributed, but have not
begun migrating (Figure S2, A1 and A2). In the treated embryos,Chemistry & Biology 16,however, a segmented pattern formed and discrete blocks of
cells were evident (Figure S2, D1 and D2). At slightly later stages
the XlDCT+ cells had migrated ventrally in the treated embryos
(Figures S2E and S2F compared with S2B and S2C) and formed
the distinctive segmented pattern seen in the treated embryos at
later stages (Figure 1D).
Effect of NSC 84093 on the Migration
of Other NCC-Derived Cells
To investigate if NSC 84093 affected the migration of other NCC
derived cells, we looked at the anterior cranial NCC, the irido-
phores, and the dorsal root ganglion. Cranial NCC migration at
stages 22 to 32 was unaffected, as assayed by in situ hybridiza-
tion using the molecular marker SOX-10, though interestingly
some segmentation of the SOX-10 pattern can be seen in the
trunk (Figures 3A and 3B) (Honore et al., 2003). Iridophores
appear iridescent silver to gold by reflecting light, and they can
be seen in their postmigration position on the embryos devel-
oping intestine in both wild-type and NSC 84093-treated
embryos The NSC 84093-treated embryos clearly show the
lack of melanophores in the ventral tail region (Figure 3, C1
and C2). Dorsal root ganglion (DRG) cells, which are derived
from the trunk neural crest, were marked by antibody staining
with b-tubulin III (Lin et al., 2007). Stained embryos were
sectioned to reveal the position of the DRG. In both treated
and control embryos, the DRG are in their normal position
between the somites and the neural tube (Figure 3, D1 and D2).
NSC 84093 Has the Pharmacological Properties
of an MMP Inhibitor
We performed structure activity relationship (SAR) analysis on
a number of other compounds shown to be similar to NSC
84093 by their pairwise Tanimoto scores. Most of these
compounds showed a similar phenotype to NSC 84093, except
for NSC 1013 (Figure 4, A1–A6). All of them contain a quinoline
scaffold (Figure 1B, boxedarea), suggesting that theyhavepoten-
tial affinity for metal ions (Hruby et al., 2004). However, quinolin-
8-ol itself had no effect on melanophore migration (Figure 4, A7).
To further investigate whether NSC 84093 activity is dependent
upon metal ions, we added various cations to see if they could93–104, January 30, 2009 ª2009 Elsevier Ltd All rights reserved 95
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MMPs in Xenopus Melanophore MigrationFigure 3. NSC 84093 Does Not Affect the Migration of Other NCC Derived Cells
(A andB) Effects on early cranial neural crestmigrationwith the application of NSC 84093 using themolecular marker SOX-10. A1–3 shows themigration of cranial
neural crest cells in untreated control embryos. B1–3 shows SOX-10 expression in embryos treated with 40 mMNSC 84093. A1 and B1 show stage 24, A2 and B2
are stage 26, and A3 and B3 are stage 30. Black arrows show the early segmented migration of trunk NCC in NSC 84093-treated embryos. White arrows indicate
the migration of cranial NCC.
(C) Effects of NSC 84093 on themigration of trunk NCC-derived iridophores. C1 shows an untreated control embryo with the normal iridophore (iridescent gold to
copper pigmented cells) position on the developing intestine (black arrow). C2 shows a NSC 84093-treated embryo with the segmented pattern of melanophores
on the dorsal side of the embryo, where iridophores havemigrated normally (black arrow). Both embryos are at stage 48, after iridophore migration. Diamond (A)
represents the lateral pigment stripe; arrowhead (:) represents the dorsal pigment stripe.
(D) Effects of NSC 84093 on the migration of trunk NCC-derived dorsal root ganglion (DRG) cells. DRG cells are visualized with the neural specific antibody
b-tubulin III and DAB staining. Transverse sections are shown at a point in themid trunk section. D1 shows the normal migration of DRG cells between the somites
and the neural tube in an untreated control embryo. D2 shows themigration of DRG cells in 40 mMNSC 84093-treated embryos. Black arrows indicate the stained
DRG cells. Both embryos are at stage 48. n represents the notochord, nt shows the neural tube, s represents the somite. All embryos are shown in lateral view,
with anterior to the left.rescue the phenotype seen in treated embryos. The addition of
manganese ions, magnesium ions, calcium ions, or ferrous iron
with 1 mM NSC 84093 did not rescue the segmented pattern
seenwith the application of NSC 84093 (Figure 4, B1–B5). Ferrous
iron did partially rescue the migration of melanophores to the tail.
Only the addition of zinc ions was able to restore the complete
normal melanophore migration pattern (Figure 4, B6). The lowest
concentration of zinc ions that was able to rescue migration was
30 nM (data not shown). The ability of both quinolin-8-ol and NSC
84093 to complex with zinc ions was further confirmed using
in vitro titration assays (Figure S4). Ferrous iron can complex
with both quinolin-8-ol and NSC 84093, but somewhat higher
concentrations of ferrous iron are needed to achieve 50%96 Chemistry & Biology 16, 93–104, January 30, 2009 ª2009 Elsevicomplexation compared with zinc (data not shown). It has been
shown that other MMP inhibitors can inhibit heme enzymes, sug-
gesting an interaction with Fe (Jacobsen et al., 2008). Impor-
tantly, when zinc ions were added to the embryo buffer after
the application of the compound, the phenotype could not be
rescued (data not shown). This strongly suggests that the
compound is not simply sequestering zinc ions away from the
developing embryo, which is also supported by the lack of activity
of the parent 8-hydroxyquinoline scaffold (Figure 4, A7).
Because MMPs are zinc-dependent enzymes and one of the
potential molecular targets of NSC 84093, we set out to deter-
mine if NSC 84093 can inhibit MMPs. We previously reported
the expression of MMP-14 in migrating neural crest cellser Ltd All rights reserved
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MMPs in Xenopus Melanophore Migration(Harrison et al., 2004). We have not identified any other MMPs
expressed in the neural crest. MMP-2 showed expression at
the same stages as MMP-14, but in tissues of the embryo that
surround the migrating front of MMP-14 expressing neural crest
cells (Figures 5A and 5B). MMP-2 was first seen to be ex-
pressed at stage 24 in the head mesenchyme (Figure 5, B1);
at stage 26, expression was seen in the head mesenchyme
and presomitic mesoderm (Figure 5, B2). In stage 30 embryos,
MMP-2 showed localization to both head and trunk mesen-
chyme (Figure 5, B3). These are coincident with areas into
which anterior and trunk NCC will migrate. By stage 34, expres-
sion was seen throughout the head, in the lateral mesoderm,
and surrounding the somites (Figure 5, B4), as confirmed by
sectioning (data not shown). Reverse-transcriptase polymerase
chain reaction (PCR) analysis confirmed that expression of
MMP-14 started just before MMP-2 (Figure 5C). TIMP-2
expression, which is thought to be necessary for MMP-14-
mediated activation of MMP-2 (Kinoshita et al., 1998), starts
at the same time as MMP-2 and at the same relative level of
expression (Figure 5C).
Figure 4. SAR Analysis and Ion Rescue Experiment of NSC
84093
(A) A series of analogs and compounds showing similar phenotypes to
NSC 84093, ranked by pairwise Tanimoto coefficient scores. The dose
tested is shown in mM. Dose-response curves have been done for all
(Figure S1 for NSC 84093 and data not shown). Quinoline-8-ol is the
scaffold compound used to synthesize the derivative compounds.
(B) Ion rescue experiment where embryos were treated with various
ions at 500 nM and NSC 84093 at 1 mM. Note the embryo treated
with zinc shows a rescue of the migration phenotype compared with
the others. All embryos are shown in lateral view, with anterior to the
left.
To examine whether NSC 84093 could inhibit Xenopus
MMP-2 activity, gelatin zymography was employed
(Leber and Balkwill, 1997). We prepared stage 38 embryo
lysates and saw a dose-dependent effect of NSC 84093
on Xenopus MMP-2 activity (Figure 6, A1). MMP-14 is
a collagenase, and therefore is not amenable to gelatin
zymography and could not be tested. One of the advan-
tages of chemical genomics is the ability to transfer
compounds to other species. To investigate if NSC
84093 was able to act as an MMP inhibitor of human
MMPs, we assayed recombinant human MMP-2. Not
only did NSC 84093 inhibit human MMP-2 activity, but it
also showed a stronger level of inhibition than in Xenopus
embryo lysate zymograms (Figure 6, A2).
NSC 84093 Demonstrates, In Silico,
the Properties of an MMP Inhibitor
To confirm that NSC 84093 can act as a putative MMP
inhibitor, we used an in silico docking approach. The
potential binding sites and efficiency of binding of NSC
84093 to various MMPs was assessed. A range of human
MMP catalytic domains was chosen for these analyses,
as well as bovine carboxypeptidase A (Rees et al., 1983),
which is not a member of the MMP family but is a zinc-
dependent protease. As a control, two knownMMP inhib-
itors, Batimastat and BBH, were also extracted from the Protein
Data Bank (PDB) files, set up for AutoDock, and docked into the
MMP structures. The ligand NSC 84093 could be docked
successfully in all cases to give reasonable chemistry and bind-
ing energies that on average were 1.51 Kcal/mol lower than Ba-
timastat and 0.90 Kcal/mol lower than BBH. Batimastat, BBH,
and NSC 84093 are all projected to have weaker binding to the
negative control bovine carboxypeptidase A. Crystal structures
of the XenopusMMPs are currently unavailable, which thus pre-
vented their investigation. Batimastat and BBH were tested on
developing Xenopus embryos and were found to either exert
no effect or to give nonspecific effects, possibly due to problems
of penetration into the embryo (data not shown). To investigate
the potential binding modes of the ligand NSC 84093 to
MMPs, MMP-14 was chosen because it was a potential target
for NSC 84093. The ligand NSC 84093 was selected from the
AutoDock NCI diversity set and prepared for docking to the
MMP-14 structure (1BBQ) using a variety of procedures (see
Experimental Procedures). Although the relative rankings
between the different docking experiments were different, theChemistry & Biology 16, 93–104, January 30, 2009 ª2009 Elsevier Ltd All rights reserved 97
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MMPs in Xenopus Melanophore MigrationFigure 5. Expression Patterns of MMP-14 and MMP-2 in the Developing Embryo
MMP-14, previously reported in Harrison et al. (2004): (A1) stage 24, (A2) stage 26, (A3) stage 30, (A4) stage 34.MMP-2: (B1) stage 24, (B2) stage 26, (B3) stage 30,
(B4) stage 34.
(C) The temporal expression pattern of MMP-14,MMP-2, and TIMP-2 during early Xenopus embryogenesis. Semiquantitative reverse transcriptase PCR analysis
shows thatMMP-14 expression is strong from stage 15 onward. MMP-2 and TIMP-2 expression is first seen from stage 20 onward. Arrows show areas of expres-
sion. All embryos are shown in lateral view, with anterior to the left.observed top binding modes were highly similar. The interac-
tions were those observed in Figure 6 (B1), in which we have
drawn the zinc binding atom bonds in a dashed yellow line. Using
the optimized Zn parameters, we obtain ligand-metal ion
distances between the O and Zn of 1.92 A˚ and between N and
Zn 1.90 A˚ in the top solution. The second-best solution has
a distance of 1.7 A˚ between the O and Zn (Figure 6, B2). These
other parameter sets introduce variation of these distances up
to 2.8 A˚ for the O and 2.7 A˚ for N in the top docking solutions.
In all cases, the ligand fits snugly into the binding pocket and
with reasonable coordination geometry. These in silico results
were confirmed by the in vitro titration assay, which confirms
that the quinolin-8-ol scaffold compound acts as the zinc binding
group of NSC 84093.
Figure 6. Gelatin Zymography of NSC 84093 on both Xenopus and Human MMP-2
(A1) Stage 38 embryo lysates (one embryo per lane), with stated concentrations of NSC 84093.
(A2) Recombinant human MMP-2 (1 and 2 ng) with stated concentrations of NSC 84093. Zymograms show both latent and activated MMP states.
(B) The top two binding modes of NSC 84093 to the M chain of 1BQQ, predicted by AutoDock using the optimized Zn parameters suggested by Hu and Shelver
(2003). The Zn ion in shown in magenta. In B1 the distance between the O and Zn is 1.92 A, and between N and Zn 1.90 A, and the free binding energy was
10.1 kcal/mol. In B2 the O Zn distance is 1.7 A and the energy of free binding 9.8 kcal/mol.98 Chemistry & Biology 16, 93–104, January 30, 2009 ª2009 Elsevier Ltd All rights reserved
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MMPs in Xenopus Melanophore MigrationFigure 7. Dose-Dependent Effect on Melanophore Migration Seen with Increasing Concentrations of MMP-2 and MMP-14 MO
All embryos are stage 38. (A1) Control embryo, (A2) embryo treated from stage 15 onward with 40 mMNSC 84093, (A3) embryo injected with 150 ng MMP-2 MO,
(A4) embryo injected with 50 ngMMP-14MO, (A5) embryo injected with 30 ng each of MMP-2 andMMP-14 MO. (B1–3) Graphs showing the effects of increasing
concentrations of MO on melanophore migration. (B1) MMP-2, (B2) MMP-14, and (B3) MMP-2 and MMP-14 injected together. Numbers above the bars corre-
spond to the number of embryos injected. All embryos are shown in lateral view, with anterior to the left.A Reduction in MMP-14 Leads to Inhibition
of Melanophore Migration
It is known that MMP-2 can be activated by MMP-14 (Kinoshita
et al., 1998), and it has been proposed that this is also the case in
Xenopus (Hasebe et al., 2007). To investigate the function of
MMP-2 and MMP-14 individually and in combination, specific
antisense MOs were injected into the animal pole area of both
blastomeres of 2-cell-stage embryos to ensure delivery to the
neural tissues. In vitro translation experiments showed that the
MMP-2 MO and MMP-14 MO were functional and dose depen-
dent (Figure S3). A scrambled sequence MO (CMO) was used as
a control in both embryos and in vitro translation assays. A dose-
dependent inhibition of melanophore migration was seen with
a serial dose of MMP-14 MO (Figure 7, A4 and B2). Injection of
MMP-14 MO causes a partial, and at higher concentrations
complete, loss of the dorsal and lateral stripes (Figure 7, B2). A
weaker dose-dependent inhibition of melanophore migration
was seen with increasing amounts of MMP-2 MO (Figure 7, A3
and B1). MMP-2 MO leads to a decrease in melanophores only
on the ventral side of the tail. Coinjection of MMP-2 and MMP-
14 MOs gives an effect similar to the MMP-14 MOs, but at lower
concentrations (Figure 7, A5 and B3), suggesting that the two
work in tandem to mediate melanophore migration. The MMP-
14 and MMP-2 MOs did not at any point give the segmented
phenotype seen in NSC 84093-treated embryos. These results
were confirmed using in situ hybridization with the probe XlDCT
at stage 32 (data not shown). Inhibition of the lateral pigment
stripe was seen at stage 32 with high doses of MMP-2 MO.
The relevant numbers of MO loss-of-function and control
embryos showing the extent of migration are shown in Figure 7B.
In the control embryo, pigment can clearly be seen in the dorsal
and lateral stripes (Figure 7, A1).
DISCUSSION
Chemical Genomics Identifies a Putative Novel
MMP Inhibitor
NSC 84093 was identified in a forward chemical genomic screen
as affecting melanophore migration in developing Xenopus lae-
vis embryos. It has not previously been reported to have an effect
on cell migration. The segmented pigment phenotype (Fig-
ure 1D), to the best of our knowledge, has also not been previ-
ously observed. Using application of NSC 84093, we show an
early segmental arrangement of the trunk XIDCT+ melanoblastsChemistry & Biology 16, 93–104, January 30, 2009 ª2009 Elsevier Ltd All rights reserved 99
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MMPs in Xenopus Melanophore Migration(melanoblasts precede the more differentiated melanophores)
(Figure S2). This pattern gives rise to the later segmented dorsal
pattern (Figure 1D). Melanoblasts migrate between the neural
tube and the somite, but then stop and do not continue to
migrate either ventrally and/or caudally. Evidence of Xenopus
neural crest cells primarily located to the midpoint of the somite
has been reported (Collazo et al., 1993; Krotoski et al., 1988).
NSC 84093 seems to act mainly on melanophores because
neural crest derivatives such as cranial neural crest, iridophores,
and the dorsal root ganglia are not affected. However, this does
not rule out the possibility that other neural crests are also
affected, especially because SOX10 expression in NSC 84093-
treated embryos also shows the characteristic segmented
pattern.
The other aspect of the NSC 84093 phenotype is a lack of
ventral tail melanophores. The segmented pattern and the inhibi-
tion of ventral tail melanophore migration could be caused by
NSC 84093, inhibiting different molecular targets. Alternatively,
they could be the consequence of the same event; for example,
if 84093’s target changes the adhesion properties on the somite
surface, this would cause the melanophores to become
restricted, a segmented pattern would arise, and the melano-
phores would be prevented from moving to the ventral side of
the tail. Melanophores are observed on the somite surface, as
seen in Figure 1. The somite surface is known to be extracellular
matrix (ECM) rich (Allenspach and Clark, 1988). Somites have
developed at this early stage (St 26), when melanoblasts have
arisen. It has been proposed that cell migration is dependent
on adhesivity, with migration proceeding at its fastest rate
when adhesion is neither too strong nor too weak (Schwartz
and Horwitz, 2006). Therefore, changes in adhesion between
the melanoblasts and somites due to the compound could
have the effect of stopping migration. The segmented and
ventral tail phenotypes might thus be distinct biological events
but caused by inhibiting the same molecular target or distinct
events by different target proteins. Further investigation will be
needed to clarify this situation.
The segmented pigment stripe of the NSC 84093 embryos
treated at low concentrations (Figures 1D and 1F and Figure S1)
was not seen with MMP-2 or MMP-14 morphant embryos on
their own or in combination. However, at higher concentrations
of NSC 84093, the segmented pattern was gradually lost in favor
of a complete block inmigration (FigureS1, panel 4),which is very
similar to the effect of MO knockdown of MMP-14 at 80 ng and
MMP-14 and MMP-2 together at 50 ng (compare Figure 7, A4
andA5, andFigure S1, panel 4). Fromour loss-of-function assays
with MMP-2, it seemed that MMP-2 only affects the migration
of melanophores to the ventral side of the tail when assayed
at stage 38. This is most easily explained by melanophores
migrating in an anterior-posterior wave. MMP-2 loss-of-function
only delays their migration, so the ventral stripe is formed last. An
alternative is the morpholino is diluted during growth of the
embryo and its effect is lost with embryo development. Indeed
when stage 32 embryos are investigated, lateral stripe melano-
phore migration was inhibited, although again higher concentra-
tions are needed than with theMMP-14MOwhereas by stage 38
the lateral stripe appears normal (data not shown).
Through the application of NSC 84093 (Figure 1) and the
MMP-2 and MMP-14 knockdown assays (Figure 7), we demon-100 Chemistry & Biology 16, 93–104, January 30, 2009 ª2009 Elsevstrate that the ventral tail melanophores of the dorsal pigment
stripe progress ventrally, down the tail of the embryo, on the
somite surface. This can clearly be seen in Figure 2H (arrow).
They do not seem to circumnavigate the tail as previously
suggested (Collazo et al., 1993).
At higher concentrations, NSC 84093might inhibit metallopro-
teinases more broadly as seen with MMP-2 and MMP-14,
leading to a complete block in melanophore migration. MMP
inhibitors tend to be broad spectrum in the enzymes they bind
to and thus exert their effect to a differing degree across the
whole family of MMPs, and indeed ADAMs (A disintegrin and
metalloproteinase domain) and ADAMTS (A disintegrin andmet-
alloproteinase domain with thrombospondin domains) enzymes
as well (Agrawal et al., 2008; Jacobsen et al., 2007).
We speculate that at lower concentrations, NSC 84093 is
potentially inhibiting a specific metalloproteinase. This could
include an MMP or an ADAM or ADAMTS. There are other
zinc-dependent proteins present in the embryos at this time
and many proteins use zinc as a cofactor (Anzellotti and Farrell,
2008). However, given the evidence for MMP inhibition at high
concentrations combined with the in silico data presented, we
believe an MMP is the most likely target. Further investigation
will need to be undertaken to ascertain the low concentration
target of NSC 84093. At higher concentrations, NSC 84093 could
be inhibiting a broader spectrum of metalloproteinases including
MMP-14 and/or MMP-2. NSC 84093 still shows some specificity
even at higher concentrations because it does not affect the
migration of embryonic macrophages, which we have shown
are dependent upon the function of MMP-7, MMP-9, and
MMP-18 (Tomlinson et al., 2008 and data not shown).
There has been progress in identifying, and in some cases
functionally characterizing, the various metalloproteinases ex-
pressed in the trunk region of the Xenopus embryo during NCC
migration. Such proteins are possible candidates for the tar-
get of NSC 84093 at low concentrations. These include two
members of the Tolloid-like family of metalloproteases, Xolloid-
related (Xlr) (Dale et al., 2002) and BMP-1 (Goodman et al.,
1998); ADAMs such as ADAM13, Xmdc9, and 11a (Alfandari
et al., 1997; Cai et al., 1998); and ADAMTS1 (Suga et al., 2006).
In the mouse, MMP-8 is expressed in migrating NCCs (Giamber-
nardi et al., 2001). XenopusMMP-8 has yet to be identified.
From our zinc ion rescue (Figure 4, B6), in silico docking exper-
iments (Figure 6B), and titration assays (Figure S4), we conclude
that the phenolic component of NSC 84093 is at least partly
acting as a zinc-binding group, possibly in conjunction with the
neighboring secondary amine as shown by the docking experi-
ments (shown in Figure 6B). The branched structure of the
compound (shown in Figure 1B) and the docking experiments
indicate that the side chains of NSC 84093 are able to interact
with the subsite pockets of the catalytic domain of MMPs
(Figure 6B). TheMMP’s active site consists of six loosely defined
subsites, three of which are located on either side of the catalytic
zinc ion (Jacobsen et al., 2007). It seems clear that the side
chains of NSC 84093 could occupy these pockets in silico and
therefore inhibit enzyme activity. However, it might also be the
case that the zinc binding site provides specificity of interaction
as well (Agrawal et al., 2008). Docking NSC 84093 with bovine
carboxypeptidase A suggests that NSC 84093 is probably not
a promiscuous inhibitor of zinc-dependent enzymes, althoughier Ltd All rights reserved
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dependent proteins. In vivo, a number of similar compounds
based on the 8-quinolinol scaffold, as judged by Tanimoto
scores, also had an effect on melanophore migration except
for NSC 1013 (Figure 3A). It might be that the nitro group of
NSC 1013, which might be reduced in vivo, binds to a different
protein and/or is sequestered away from the melanophores.
The 8-quinolinol scaffold and branched structures of these
compounds appear critical for their phenotypic effect.
In the human MMP-2 zymograms, NSC 84093 showed a high
level of inhibition of MMP-2 activity, again in a dose-dependent
fashion (Figure 6, A2), as with the Xenopus MMP-2 zymograms
(Figure 6, A1). These results further establish that NSC 84093
can act as an MMP inhibitor. The increased inhibition levels
seen in the human MMP-2 zymograms compared with the Xen-
opus MMP-2 zymograms could be due to many factors,
including the heterogeneity of an embryo lysate and the evolu-
tionary divergence between human and Xenopus MMPs.
MMP-14 and MMP-2 Are Required
for Melanophore Migration
Human MMP-14 was the first membrane-bound MMP to be
identified (Puente et al., 1996) and was subsequently shown to
be a specific activator of pro-MMP-2 (Sato et al., 1996). This
MMP has received a great deal of attention due to its important
function in the progression of malignant tumors (Sato et al.,
2005). MMP-14 functions in cancer progression, both by the
activation of pro-MMP-2 (Itoh et al., 2001) and by modification
of the ECM type I collagen and other substrates (d’Ortho et al.,
1997). The main basement membrane target of MMP-2 is type
IV collagen (Hornebeck et al., 2002; Itoh et al., 2001). The mouse
knockout of MMP-14 gives a severe phenotype, including prob-
lems in craniofacial development, dwarfism, and skeletal and
extraskeletal connective tissue abnormalities (Holmbeck et al.,
1999). The importance of MMP-14 and MMP-2 is emphasized
by the fact that cancer cells proliferate within an embedded
dense three-dimensional matrix that is composed largely of
type I collagen. To metastasize they need to modify this matrix
(Sato et al., 2005). Their expression patterns reflect these func-
tions, with MMP-14 expressed on the leading edge of metastatic
cancer cells acting as an invasion-promoting protease (Seiki
et al., 2003), and MMP-2 localized in the stromal cells
surrounding the tumor (Poulsom et al., 1992). Expression levels
of MMP-14 have been closely associated with tumor invasive-
ness (Sato et al., 2005).
It has been shown that MMP-14 complexes with the endoge-
nous MMP inhibitor TIMP-2 to activate MMP-2 (Itoh et al.,
2001). The same interaction has been proposed to occur during
Xenopus metamorphosis (Walsh et al., 2007). The temporal and
spatial expression of MMP-2, MMP-14, and TIMP-2 in early
Xenopusembryogenesis (Figure 5) suggests a similarmechanism
occurring in the early frog embryo. MMP-14 expression on
the migrating melanophores and MMP-2 expression in the
surrounding mesenchyme along with the MO knockdowns (Fig-
ure 7) demonstrate that they both play a functional role in
promoting the migration of melanophores in the developing
Xenopus embryo. We speculate that in combination with TIMP2,
MMP-14 is likely to be cleaving pro-MMP-2 in the encapsulating
tissues, which in turn would be able to modify the surroundingChemistry & Biology 16, 9ECM for the subsequent melanophore migration. Similar expres-
sionpatterns forMMP-2areseen in chickembryosat comparable
stages in development, with MMP-2 being deposited by the
mesenchymal cells (Cai et al., 2000; Duong and Erickson, 2004).
Despite the potential of chemical genomics, one of the biggest
challenges to this new and emerging field is that of target identi-
fication. Although significant advances have been made in this
area (Boshoff and Dowd, 2007; Burdine and Kodadek, 2004;
Jung et al., 2005; Mitsopoulos et al., 2004), as yet there is no reli-
able and general method to identify the molecular target of
a compound of interest. However, it is still feasible to narrow
the range of potential molecular targets that need to be investi-
gated for a novel bioactive compound (Luesch, 2006; Parsons
et al., 2006). Here we present several approaches that could
be transferable to other investigations of small, biologically
active compounds. These include in silico docking experiments,
an approach that is becoming increasingly important in struc-
ture-based drug design (Kitchen et al., 2004; Orry et al., 2006)
and has the potential to play a further part in chemical geno-
mic investigations (Figure 6B), an in vitro biochemical assay
(Figure 6A), and the use of competition or rescue experiments
(Figure 4B), which could be expanded to enzyme substrates or
other candidate interactors.
SIGNIFICANCE
This study illustrates some of the advantages of a chemical
genomic approach to investigate developmental processes,
especially when used with complementary loss-of-function
experiments. We identified NSC 84093 from a forward chem-
ical genomic screen targeting melanophore (pigment cell)
phenotypes and show it to be capable of acting as an MMP
inhibitor. Fine temporal intervention in combination with
other assays presented here has allowed us to show that
NSC 84093’s molecular target(s) act early in melanophore
development to generate a segmented phenotype and
slightly later to inhibitmelanophoremigration into the ventral
tail region. Other neural crest derivatives are hard to distin-
guish, but we do not see any effects on cranial neural crest,
iridophores, and development of the dorsal root ganglia. As
such NSC 84093 provides us with a unique molecular tool
to investigate melanophore migration. In addition, MO (anti-
sense oligonucleotide) knockdown studies on MMP-14 and
MMP-2 illustrate thatMMPs play an essential role inmelano-
phore migration during development and could be potential
targets of NSC 84093. These results not only have implica-
tions in the context of developmental biology, but also have
significance in understanding NCC migration and the roles
of MMPs in the processes of cellular migration.
EXPERIMENTAL PROCEDURES
All experiments were performed in compliance with the relevant laws and insti-
tutional guidelines at the University of East Anglia. The research has been
approved by the local ethical review committee according to UK Home Office
regulations.
In Vitro and MO Assays
Xenopusembryoswere obtainedaspreviously described (Harrison et al., 2004).
MO antisense oligonucleotides were microinjected into the two animal poles3–104, January 30, 2009 ª2009 Elsevier Ltd All rights reserved 101
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by Gene tools based on supplied GenBank sequences (MMP-14 accession
number AY6333953, MMP-2 accession number NM-001087228). TheMMP-14
MO sequence is (50-CCAGGCTGCTCTCAGAGGCTCCATC-30). MMP-2
morpholino sequence is (50 -CATGCTAAAGCCTGACTTTCTGCCG30). The
scrambled sequence control morpholino (CMO) sequence is (50-CCTCTTACC
TCAGTTACAATTTATA30) MOs were subjected to in vitro translation assay
before use (TNT coupled reticulocyte system, Promega), according to previ-
ously published methods (Abu-Elmagd et al., 2006).
In Situ Hybridization and Histology
MMP-2 in situ probes were generated from a MMP-2 pGEM clone. Briefly,
primers were designed at the start and stop of PCRT7_GelAwtFLAG (Hasebe
et al., 2007). Primer sequences are as follows: MMP-2 F (50-CACCATGCGGA
CAATTA-30), MMP-2 R (50-GCTACGCTGCGACTACAAG-30 ). A standard PCR
protocol was followed using Pfu polymerase (Promega) for its high fidelity.
We performed 30 amplification cycles with a 55Cannealing and a 72Cexten-
sion temperature, and a final 72C 10 min incubation with 1 ml of Taq poly-
merase (Invitrogen) was done to add A residues for the subsequent TOPO
cloning step. The purified PCR product was then ligated into PGem-T Easy
(Promega). Clones were then validated by DNA sequencing. Whole-mount
in situ hybridization assays were done as previously described (Harrison
et al., 2004). Paraffin wax sectioning was done to examine internal melano-
phore localization according to previously published methods (Harrison
et al., 2004).
Immunohistochemistry
Immunohistochemistry was performed on stage 48 embryos to visualize the
dorsal root ganglion cells. Embryos were fixed overnight in Dents fix (4:1 meth-
anol:DMSO) and permeabilized in phosphate-buffered saline (PBS) containing
0.5% Triton X-100 and a 10 min proteinase K digestion and blocked with 2%
Boehringer Blocking Reagent (Roche). Primary antibodies used were b-tubulin
III (Sigma T2200, 1:100). Diaminobenzidine tetrahydrochloride (DAB) staining
was achieved with a 2:1 solution of DAB and nickel chloride in PBS containing
0.5% Triton X-100. Paraffin sections prepared as outlined above.
Compound Application
NSC 84093 was identified in a screen of 3000 compounds looking for inhibitors
of pigment patterning during Xenopus development. NSC 84093 and other
compounds used in the study were obtained from the Diversity set, National
Cancer Institute (NCI), and prepared as 10mM stock solutions in dimethyl sulf-
oxide. The embryos were arrayed by Pasteur pipette, 10 embryos per 5 cm
Petri dish containing 10 ml of 0.1XMMR (Marcs modified ringers, respectively,
supplemented with 50 mg/ml gentamycin sulfate). Embryos were grown at
18C, staged according to previously published criteria (Nieuwkoop and
Faber, 1994), and photographed using previously published methods (Harri-
son et al., 2004).
Metal Ion Rescue Experiments
Coaddition of various ions at 500 nM included manganese ions (MnCl2),
magnesium ions (MgCl2), calcium ions (CaCl2), zinc ions (ZnSO4), and ferrous
iron citrate (C6H5FeO7) with the application of the NSC 84093 compound at
1 mM. Assays performed with 10 embryos per 5 cm Petri dish containing
10 ml 0.1XMMR, supplemented with 50 mg/ml gentamycin sulfate.
In Vitro Zinc Titration Assays
The wavelength of maximum absorption change was determined by titrating
a 1 mM MeOH solution of quinolin-8-ol or NSC 84093 (500 ml in a 1 ml glass
cuvette) with 20 mM aqueous ZnSO4 in 1 ml steps and acquiring UV/VIS
spectrum on a Perkin Elmer Lambda 25 UV/VIS spectrometer. This
maximum was determined to be 405 nm (for NSC 84093) and 375 nm (for
quinolin-8-ol). The titration curves for quinolin-8-ol and NSC 84093 were
determined using a multiwell plate reader (Dynex MRXTC Revelation) at
A405. The final concentration in each well (total volume 100 ml) of quinolin-
8-ol and NSC 84093 (methanolic stocks) was 100 mM. The final concentration
of zinc ions (aqueous stocks) were decreasing by a factor of 10 starting with
100 mM down to 1 nM.102 Chemistry & Biology 16, 93–104, January 30, 2009 ª2009 ElsevTanimoto Pairwise Coefficient Analysis
To allow a pairwise comparison and ranking of analogs of compound NSC
84093, a web-based Tanimoto algorithm was used, calculated by using the
Chembank website (http://chembank.broad.harvard.edu/) and the Daylight
fingerprint algorithm. SMILES (Simplified Molecular Input Line Entry Specifica-
tion) of the compound under investigation were obtained from the NCI website
(http://dtp.nci.nih.gov/docs/dtp_search.html) and used to perform a similarity
search on the Chembank website (http://chembank.broad.harvard.edu/), with
the following variables defined: Tanimoto similarity metric and a similarity
threshold (distance) of 0.8.
Gelatin Zymography
Stage 38 embryo lysates were dissected before lysis to exclude the head
region and the yolk area. Human recombinant MMP-2 was obtained from
R&D systems (902-MP). Gelatin zymography was done as previously
described (Leber and Balkwill, 1997). Both embryo lysates and recombinant
MMP-2were activated before being assayed. Activationwas achieved by add-
ing 4-aminophenylmercuric acetate (A9563) to a 1 mM final concentration and
incubating at 37C for 1 hr.
In Silico Docking Experiments
MMP structures (3AYK, 1QIB, 2DIO, 1BZS, 1MMP, 1UTT, 1RM8, 1BBQ, and
5CPA) were downloaded from the PDB and prepared for AutoDock 3.0 using
the AutoDockTools graphical interface. Hydrogens and Kollman charges were
added. The Zn2+ charge was set to a value of +0.95 as suggested by Hu and
Shelver based on their zinc binding group optimization study (Hu and Shelver,
2003). Autodock 3.0 does not have Zn parameters, so the optimized parame-
ters of Hu and Shelver were assigned (radius = 0.87 A˚, well depth = 0.35 kcal/
mol). The structure of NSC 84093 was taken from the NCI diversity set avail-
able in AutoDock format from the AutoDock website. A grid size of 62 3 62 3
62 was chosen with a grid spacing of 0.375 A˚, which completely covers the
binding pocket. The Lamarckian genetic algorithm was chosen as the opti-
mizer with the default settings. As a control, two known MMP inhibitors, Bati-
mastat and BBH, were also extracted from PDB files, set up for AutoDock, and
docked to the MMP structures.
To investigate the potential bindingmodes of the ligandNSC 84093 toMMP-
14, the MMP structure 1BBQ was employed. The ligand NSC 84093 was
selected from the AutoDock NCI diversity set and prepared for docking
following the recommended procedure from the AutoDock manual. A grid
size of 80 3 80 3 80 with a spacing of 0.225 A˚, centered on the Zn atom of
the binding pocket, was used to sample the interactions with the ligands.
AutoDock 4.0 has Zn force field parameters, but we also experimented with
the Stote and Karplus parameters (r = 1.1 A˚, epsilon = 0.25 kcal/mol, q = +2)
(Stote and Karplus, 1995) and the optimized parameters of Hu and Shelver
(r = 087 A˚, well depth = 0.35 kcal/mol, q = +0.95) (Hu and Shelver, 2003).
We also tried deprotonating the ligand prior to docking.We chose a population
size of 250, a function evaluation maximum of 25,000,000, and 30 runs, but
otherwise stuck with the default docking parameters.
SUPPLEMENTAL DATA
The Supplemental Data include four figures and can be found with this
article online at http://www.cell.com/chemistry-biology/supplemental/S1074-
5521(08)00002-7.
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